Cargando…

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

BACKGROUND: The inflammatory pathology observed in severe COVID-19 disease caused by the 2019 novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by elevated serum levels of C reactive protein (CRP) and cytokines, including interferon gamma, interleukin 8 (IL-8), and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Montesarchio, Vincenzo, Parrella, Roberto, Iommelli, Chiara, Bianco, Antonella, Manzillo, Elio, Fraganza, Fiorentino, Palumbo, Cristiana, Rea, Gaetano, Murino, Patrizia, De Rosa, Rosanna, Atripaldi, Luigi, D’Abbraccio, Maurizio, Curvietto, Marcello, Mallardo, Domenico, Celentano, Egidio, Grimaldi, Antonio Maria, Palla, Marco, Trojaniello, Claudia, Vitale, Maria Grazia, Million-Weaver, Samuel Lewis, Ascierto, Paolo Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418768/ https://www.ncbi.nlm.nih.gov/pubmed/32784217 http://dx.doi.org/10.1136/jitc-2020-001089

Ejemplares similares

Clinical Outcome Prediction in COVID-19 Patients by Lymphocyte Subsets Analysis and Monocytes’ iTNF-α Expression
por: Madonna, Gabriele, et al.
Publicado: (2021)

Could asymptomatic carriers spread the SARS-CoV-2 infection? Experience from the Italian second wave
por: Atripaldi, Luigi, et al.
Publicado: (2021)

New Insights into the Identification of Metabolites and Cytokines Predictive of Outcome for Patients with Severe SARS-CoV-2 Infection Showed Similarity with Cancer
por: Costantini, Susan, et al.
Publicado: (2023)

Sarilumab monotherapy vs sarilumab and methotrexate combination therapy in patients with rheumatoid arthritis
por: Burmester, Gerd R, et al.
Publicado: (2021)

TOCIVID-19 - A multicenter study on the efficacy and tolerability of tocilizumab in the treatment of patients with COVID-19 pneumonia. Study protocol
por: Piccirillo, Maria Carmela, et al.
Publicado: (2020)

Lean oncology: a new model for oncologists
por: Montesarchio, Vincenzo, et al.
Publicado: (2012)

Do BRAF inhibitors select for populations with different disease progression kinetics?
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

COVID-19 vaccination in adults with congenital heart disease: Real-world data from an Italian tertiary centre()
por: Fusco, Flavia, et al.
Publicado: (2021)

Serious haematological toxicity during and after ipilimumab treatment: a case series
por: Simeone, Ester, et al.
Publicado: (2014)

Corticosteroids and Delayed Conversion of SARS-CoV-2 RNA Nasopharyngeal Swabs in Hospitalized Patients With COVID 19 Pneumonia
por: Parrella, Roberto, et al.
Publicado: (2022)

Effects of the Interleukin-6 Receptor Blocker Sarilumab on Metabolic Activity and Differentiation Capacity of Primary Human Osteoblasts
por: Klinder, Annett, et al.
Publicado: (2022)

Impact of IL6R genetic variants on treatment efficacy and toxicity response to sarilumab in rheumatoid arthritis
por: Sainz, Luis, et al.
Publicado: (2023)

Sarilumab: Cytomegalovirus colitis: case report
Publicado: (2020)

Sarilumab Administration in COVID-19 Patients: Literature Review and Considerations
por: Marino, Andrea, et al.
Publicado: (2022)

Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned
por: Trojaniello, Claudia, et al.
Publicado: (2023)

Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study
por: Della-Torre, Emanuel, et al.
Publicado: (2020)

Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
por: Genovese, Mark C, et al.
Publicado: (2019)

IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab
por: Mallardo, Domenico, et al.
Publicado: (2023)

Sarilumab: patient-reported outcomes in rheumatoid arthritis
por: Crotti, Chiara, et al.
Publicado: (2018)

Population Pharmacokinetics of Sarilumab in Patients with Rheumatoid Arthritis
por: Xu, Christine, et al.
Publicado: (2019)

Sarilumab: Perforated duodenal ulcer: case report
Publicado: (2021)

Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management
por: Simeone, Ester, et al.
Publicado: (2019)

Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2
por: Corominas, Hèctor, et al.
Publicado: (2021)

Correction: Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy
Publicado: (2020)

Sarilumab use in severe SARS-CoV-2 pneumonia
por: Gremese, Elisa, et al.
Publicado: (2020)

Correlation between immune-related adverse events and response to pembrolizumab in advanced melanoma patients
por: Grimaldi, Antonio Maria, et al.
Publicado: (2015)

Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
por: Raimondo, Maria Gabriella, et al.
Publicado: (2017)

Subcutaneous Sarilumab in Patients With Rheumatoid Arthritis who Previously Received Subcutaneous Sarilumab or Intravenous Tocilizumab: An Open‐Label Extension of a Randomized Clinical Trial
por: Emery, Paul, et al.
Publicado: (2020)

High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab
por: Strand, Vibeke, et al.
Publicado: (2020)

Clinical efficacy and safety of interleukin-6 receptor antagonists (tocilizumab and sarilumab) in patients with COVID-19: a systematic review and meta-analysis
por: Yu, Su-Yeon, et al.
Publicado: (2022)

Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
por: Morello, Silvana, et al.
Publicado: (2017)

Disease–Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis
por: Lee, Eun Bong, et al.
Publicado: (2016)

Sarilumab: Thrombocytopenia during an off-label use: case report
Publicado: (2020)

Efficacy and Safety of Sarilumab in COVID-19: A Systematic Review
por: Chamlagain, Rajan, et al.
Publicado: (2021)

The Serum Metabolome of Moderate and Severe COVID-19 Patients Reflects Possible Liver Alterations Involving Carbon and Nitrogen Metabolism
por: Caterino, Marianna, et al.
Publicado: (2021)

Cardiovascular risk and dyslipidemia among persons living with HIV: a review
por: Maggi, Paolo, et al.
Publicado: (2017)

Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19
por: Trojaniello, C., et al.
Publicado: (2021)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
por: Trojaniello, Claudia, et al.
Publicado: (2021)

A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation
por: Simeone, Ester, et al.
Publicado: (2021)

Correlation between BRAF mutational status and clinical response to pembrolizumab in advanced melanoma patients
por: Simeone, Ester, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i86f9miksnpf1h4a4rklcna4sa